Adult Tumor Diseases | Bioaro

 Rare tumours are bone and soft tissue cancers with an incidence of less than 6 in 100,000 people per year. The greatest disparity in the management of rare solid tumours from the rest is due to the limited access for patients with rare cancers to clinical research studies.

More than 300 rare solid tumours have been identified to date. The only advantage to surviving some of these cancers depends on their early detection. You can now track down the genes and mutations behind such rare tumours by genetic analysis and the advanced genome sequencing technology at BioAro.

You can consult us at BioAro to take a proactive and preventative approach to your healthcare. Visit our website for more details.


Please visit us :- https://bioaro.com/

follow on us

Facebook :- https://www.facebook.com/BioAroinc/

Twitter :- https://twitter.com/bioaroinc

LinkedIn :- https://www.linkedin.com/company/bioaroinc

Comments

Popular posts from this blog

The Future of Genome Sequencing: What You Need to Know

DIABETES AWARENESS MONTH || BIOARO

How DNA Sequencing is changing Healthcare